Biodesix Reports FY25 Revenue of $88.5 Million
Total revenue is estimated to be $28.8M and $88.5M for the fourth quarter and fiscal 2025, respectively, an increase of 41% and 24% over the respective prior year comparable periods. FY25 revenue consensus $84.74M. "Biodesix finished 2025 with a strong fourth quarter delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million," said Scott Hutton, CEO. "Throughout the year, we delivered accelerating growth in our Lung Diagnostics testing revenue, driven by an increase in test volumes and continued expansion of reimbursement. We also grew our Development Services revenue while advancing key partnerships. 2025 was another significant year for Biodesix as we presented and published new clinical and health economic data that directly support both our on-market and pipeline products. Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter. I am exceptionally proud of the Biodesix team's accomplishments in 2025 and their unwavering commitment to the healthcare professionals and the patients we serve. I look forward to building on this momentum in 2026."
Discover Tomorrow's Bullish Stocks Today
Analyst Views on BDSX
About BDSX
About the author
Friedland Enterprises Acquires 5% Stake in Lulu's Fashion Lounge
- Share Acquisition: Friedland Enterprises announced the acquisition of approximately 5% of the outstanding shares of Lulu's Fashion Lounge, aiming to enhance its market influence in the fashion retail sector and potentially provide greater strategic flexibility.
- Market Signal: This acquisition indicates Friedland's confidence in Lulu's future growth potential, which may attract other investors' attention, thereby increasing Lulu's market valuation and investment appeal.
- Investment Strategy: By increasing its stake, Friedland plans to exert greater influence over Lulu's decision-making, driving business development and brand strategy, further solidifying its position in the competitive fashion industry.
- Industry Consolidation: This transaction may signal a trend of consolidation in the fashion retail sector, with Friedland's move potentially inspiring other investors to pursue similar acquisitions to seek higher market share and synergies.
Biodesix (BDSX) Q4 and FY2025 Outlook Exceeds Estimates with $28.8M Revenue
- Significant Revenue Growth: Biodesix expects FY2025 revenue of $88.5 million, a 24% YoY increase, surpassing the analyst consensus estimate of $84.65 million, indicating strong performance in the lung diagnostics sector.
- Increased Test Volumes: Test volumes reached 18,000 in Q4 and 62,600 for the year, reflecting a 23% and 15% YoY increase, respectively, showcasing the company's enhanced market demand and service capabilities.
- Lung Diagnostics Contribution: The lung diagnostics segment contributed $25.2 million in Q4 and $79.2 million for the full year, representing YoY growth of 47% and 22%, highlighting the strong growth potential of this division.
- Robust Cash Flow: Biodesix ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase from the previous quarter, providing solid financial support for future growth.
